Evotec Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Christian Wojczewski

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.6yrs
Gemiddelde ambtstermijn bestuur	2.9yrs

Recente managementupdates

Recent updates

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Nov 05

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 17

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 08

CEO

Christian Wojczewski (52 yo)

less than a year

Tenure

Dr. Christian Wojczewski serves as Chief Executive Officer of Evotec SE since July 01, 2024. He holds a diploma and a doctorate in chemistry from the Johann Wolfgang Goethe University in Frankfurt am Main....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Laetitia Rouxel	CFO & Member of Management Board	1.6yrs	€890.00k	0.029% € 418.4k
Cord Dohrmann	Chief Scientific Officer & Member of Management Board	14.2yrs	€1.48m	0.11% € 1.6m
Craig Johnstone	COO & Member of Management Board	5.8yrs	€1.18m	0.011% € 163.3k
Christian Wojczewski	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Aurelie Dalbiez	Chief People Officer & Member of Management Board	less than a year	geen gegevens	geen gegevens
Volker Braun	Executive VP and Head of Global Investor Relations & ESG	no data	geen gegevens	geen gegevens
Christian Dargel	EVP Global Head of Legal & Compliance	no data	geen gegevens	geen gegevens
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	no data	geen gegevens	geen gegevens
Ian Hunneyball	Senior Vice President of Programme Management & Clinical Operations	no data	€116.00k	geen gegevens
David Hallet	Executive Vice President	no data	geen gegevens	geen gegevens
Uwe Andag	EVP Head of Metabolic Diseases	no data	geen gegevens	geen gegevens
Christiane Honisch	SVP Head of Diagnostics	no data	geen gegevens	geen gegevens

1.6yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EVT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Roland Sackers	Independent Vice Chairperson of the Supervisory Board	5.4yrs	€95.00k	geen gegevens
Iris Loew-Friedrich	Independent Chairperson of the Supervisory Board	10.4yrs	€150.00k	geen gegevens
Duncan McHale	Member of the Supervisory Board	less than a year	geen gegevens	geen gegevens
Camilla Languille	Member of the Supervisory Board	2.4yrs	€60.00k	geen gegevens
Constanze Ulmer-Eilfort	Independent Member of Supervisory Board	3.4yrs	€85.00k	geen gegevens
Wesley Wheeler	Independent Supervisory Board	less than a year	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EVT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.

Evotec Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE, Annual General Meeting, Jun 20, 2023

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Recent updates

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Price target decreased by 22% to €10.65

Consensus EPS estimates fall by 13%

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Price target decreased by 11% to €13.64

Consensus EPS estimates fall by 69%

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 77%

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Price target decreased by 7.0% to €19.26

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Price target decreased by 7.5% to €23.00

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Evotec SE, Annual General Meeting, Jun 20, 2023

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

Price target decreased by 8.1% to €24.93

Price target decreased by 9.8% to €24.73

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Consensus forecasts updated

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Consensus forecasts updated

Consensus EPS estimates have been upgraded.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Consensus forecasts updated

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Now 22% undervalued after recent price drop

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Now 22% undervalued after recent price drop

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Investor sentiment improved over the past week

Is Now The Time To Look At Buying Evotec SE (ETR:EVT)?

Evotec SE Confirms Revenue Guidance for 2022

Is Evotec (ETR:EVT) A Risky Investment?